Quick Answer
Gain Therapeutics, Inc. reported Net Income of -$20.16 million for fiscal year 2025.
Gain Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$20.16M | +1.2% |
| 2024 | -$20.41M | +8.3% |
| 2023 | -$22.27M | -26.6% |
| 2022 | -$17.59M | -26.6% |
| 2021 | -$13.89M | -288.3% |
| 2020 | -$3.58M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$5.28M | -17.8% | +9.0% |
| June 30, 2025 | -$5.81M | +28.7% | -28.2% |
| March 31, 2025 | -$4.53M | -12.9% | -1.0% |
| September 30, 2024 | -$4.49M | +4.9% | +44.9% |
| June 30, 2024 | -$8.14M | -5.9% | -102.9% |
| March 31, 2024 | -$4.01M | +21.9% | +14.9% |
| September 30, 2023 | -$4.72M | -3.5% | +38.6% |
| June 30, 2023 | -$7.69M | -51.2% | -49.6% |
- Gain Therapeutics, Inc. showed an increase of +1.2% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Gain Therapeutics, Inc.’s net income has declined by 463.5% (from -$3.58 million to -$20.16 million).
- The most recent figure is from Gain Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: